Show simple item record Kovács, Tibor 2015-02-04T11:40:56Z 2015-02-04T11:40:56Z 2014
dc.identifier.citation pagination=1655-1660; journalVolume=155; journalIssueNumber=42; journalTitle=ORVOSI HETILAP;
dc.identifier.uri doi:10.1556/OH.2014.30021
dc.description.abstract Non-valvular atrial fibrillation is one of the most important risk factor for embolic cerebral infarcts. Besides vitamin K antagonists, recently developed novel oral anticoagulants are gaining an increasing role in its treatment. Dabigatran, rivaroxaban and apixaban are novel oral anticoagulants available in the routine clinical practice. This review summarizes their use and the corresponding guidelines in the secondary prevention of ischemic stroke, by answering questions raised in relation of a hypothetical case report.
dc.relation.ispartof urn:issn:0030-6002
dc.title Stroke-prevenció stroke után pitvarfibrillacióban - eseten alapuló áttekintés.
dc.type Journal Article 2015-01-27T11:45:54Z
dc.language.rfc3066 hu
dc.identifier.mtmt 2794840
dc.identifier.pubmed 25305723
dc.contributor.department SE/AOK/K/Neurológiai Klinika
dc.contributor.institution Semmelweis Egyetem

Files in this item



This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account